Key Insights

Highlights

Success Rate

79% trial completion

Published Results

298 trials with published results (15%)

Research Maturity

901 completed trials (45% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

11.7%

236 terminated out of 2015 trials

Success Rate

79.2%

-7.3% vs benchmark

Late-Stage Pipeline

8%

166 trials in Phase 3/4

Results Transparency

33%

298 of 901 completed with results

Key Signals

298 with results79% success236 terminated

Data Visualizations

Phase Distribution

1,605Total
Not Applicable (267)
Early P 1 (24)
P 1 (606)
P 2 (542)
P 3 (146)
P 4 (20)

Trial Status

Completed901
Recruiting336
Unknown276
Terminated236
Active Not Recruiting120
Not Yet Recruiting70

Trial Success Rate

79.2%

Benchmark: 86.5%

Based on 901 completed trials

Clinical Trials (2015)

Showing 20 of 20 trials
NCT00539162Not ApplicableRecruitingPrimary

Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women

NCT05123807Phase 2RecruitingPrimary

Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)

NCT04421963Phase 3Active Not RecruitingPrimary

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib

NCT06036810Not ApplicableRecruitingPrimary

Spanish Decision Tool for Ovarian Cancer Maintenance Therapy

NCT06824467Phase 3RecruitingPrimary

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

NCT07318558Phase 3Recruiting

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

NCT07303894Phase 2RecruitingPrimary

A Study of Isoquercetin in People With Ovarian Cancer

NCT07214779Phase 3RecruitingPrimary

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

NCT06799637Phase 1Recruiting

Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments

NCT07532148Phase 1Not Yet RecruitingPrimary

Study of CKD-215 and D215 in Adults With BRCA-mutated Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02043158Active Not RecruitingPrimary

Biobehavioral and Sociodemographic Characteristics of Long Term Survivors of Ovarian Cancer

NCT05877599Phase 1Recruiting

A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

NCT07532434RecruitingPrimary

A Bidirectional Cohort Study on Prophylactic Resection Surgery in Populations at Moderate-to-High Risk for Hereditary Ovarian Cancer

NCT05866679Phase 1SuspendedPrimary

Early Assessment of Ovarian Cancer Aggressiveness by Metabolic Imaging

NCT05287451Not ApplicableRecruitingPrimary

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study

NCT02854215Not ApplicableCompletedPrimary

Cost Utility of Radical Surgery in Ovarian Cancer

NCT04847063Phase 1Recruiting

Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies

NCT06906341Phase 2RecruitingPrimary

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

NCT03412877Phase 2Recruiting

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

NCT06618235Phase 1RecruitingPrimary

Trial of THEO-260 in Ovarian Cancer Patients

Scroll to load more

Research Network

Activity Timeline